

ABI Undervalued in Assessing Cardiovascular Risk

BY MARY ANN MOON
Contributing Writer

The ankle-brachial index, a measurement that is commonly used by vascular specialists but not by other providers, adds such important information to cardiovascular risk assessment that it could now be incorporated into that process routinely, according to investigators who performed a meta-analysis of longitudinal studies of the index and the incidence of cardiovascular events.

The index is the ratio of systolic blood pressure taken at the ankle to that in the arm. It is routinely used to assess the severity of peripheral artery disease but is also a good indicator of generalized atherosclerosis. A low ankle-brachial index (ABI) is thought to predict coronary and cerebrovascular events and mortality.

To determine whether the ABI improves cardiovascular risk assessment independently of the Framingham score in the general population, the Ankle Brachial Index Collaboration was formed, comprising investigators from all major observational studies that had “investigated longitudinally the ABI and incidence of cardiovascular events and mortality in general populations.”

The collaboration performed a meta-analysis of 16 population-based cohort studies in Europe, Australia, and the United States, said Dr. Gerry Fowkes of the University of Edinburgh’s School of Public Health Sciences and corresponding author for the collaboration.

Data processing and statistical analysis in this meta-analysis was provided by a grant from Sanofi-Aventis/Bristol-Myers Squibb Co.

The meta-analysis included 24,955 men and 23,339 women aged 47-78 years who had no known cardiovascular disease at baseline and who were followed for a median of 3-17 years.

There were more than 9,000 deaths overall, and about one-fourth of those were due to coronary heart disease or stroke.

“We found that the ABI provided independent risk information compared with the Framingham score and, when combined with the Framingham score, a low ABI approximately doubled the risk of total mortality, [cardiovascular] mortality, and major coronary events across all Framingham risk categories,” Dr. Fowkes and his associates reported (JAMA 2008;300:197-208).

An estimated 20% of the male subjects would have had their category of risk lowered if their ABI had been added to their Framingham score, which “would likely have an effect on decisions to com-

mence preventive treatment such as lipid-lowering therapy,” the authors wrote.

More important, in an estimated 1 in 3 female subjects, the category of risk would have risen from low to a higher level if their ABI had been added to their Framingham score, Dr. Fowkes and his associates noted.

The ABI is “quick and easy” to measure in the primary care or community clinic setting, can be performed by a trained nurse or other support staff, and requires

only the use of a relatively inexpensive (\$600) hand-held Doppler device, the researchers said.

Nevertheless, it is rarely used in routine clinical practice outside of vascular specialties, primarily because most providers are unaware of its value in predicting cardiovascular risk and do not know how to perform it.

The findings of this study, together with those of other recent studies, demonstrate that the incorporation of the ABI into rou-

tine cardiovascular risk assessment “may indeed be justified.”

“A new risk equation incorporating the ABI and relevant Framingham risk variables could more accurately predict risk, and our intention is to develop and validate such a model in our combined data set,” Dr. Fowkes and his associates asserted.

Dr. Fowkes has received honoraria and consulting fees from Sanofi-Aventis/Bristol-Myers Squibb.

Indications and usage

Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic

ketoacidosis. Levemir® should not be diluted or mixed with any other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

For your patients with type 2 diabetes, start once-daily Levemir®

Levemir® helps patients with diabetes achieve their A1C goal.^{1,2}

- 24-hour action at a once-daily dose^{3,4}
- Provides consistent insulin absorption and action, day after day^{3,5,6}
- Less weight gain^{7†}

References: 1. Meneghini LF, Rosenberg KH, Koenen C, Meriläinen MJ, Lüdtke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes Obes Metab*. 2007;9(3):418-427. 2. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P, for the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care*. 2006;29(6):1269-1274. 3. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. *Diabetes Obes Metab*. 2007;9(3):290-299. 4. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther*. 2006;28(10):1569-1581. 5. Danne T, Endahl L, Haahr H, et al. Lower within-subject variability in pharmacokinetic profiles of insulin detemir in comparison to insulin glargine in children and adolescents with type 1 diabetes. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17-21, 2007; Amsterdam, Netherlands. Abstract 0189. 6. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes*. 2004;53(6):1614-1620. 7. Data on file. NDA21-536. Novo Nordisk Inc, Princeton, NJ.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and Levemir® are registered trademarks of Novo Nordisk A/S.
© 2008 Novo Nordisk Inc. 133236R1

May 2008